Podcasts about moderna ceo stephane bancel

Moderna CEO Stephane Bancel discusses company earnings and the benefits of cost-cutting to offset their Covid business decline. He speaks with Bloomberg's Jonathan Ferro and Lisa Abramowicz.  See omnystudio.com/listener for privacy information.

-Andrew Hollenhorst, Citi Chief US Economist-Savita Subramanian, Bank of America Head of US Equity & Quantitative Strategy-Stephane Bancel, Moderna CEOCiti's Andrew Hollenhorst reacts to the Fed's decision to hold interest rates, saying inflation data will give the Fed the opportunity to cut rates this year. BofA's Savita Subramanian says the US will achieve a soft landing where the market adapts to higher rates. Moderna CEO Stephane Bancel reacts to better-than-expected first quarter earnings and discusses the company's upcoming RSV vaccine.See omnystudio.com/listener for privacy information.

Moderna CEO Stephane Bancel speaks with Bloomberg's Lisa Abramowicz and Jonathan Ferro about the company's fourth quarter results. See omnystudio.com/listener for privacy information.

Moderna CEO Stephane Bancel discusses the joint effort between Merck and Moderna to create a vaccine that combats skin cancer. He speaks with Bloomberg's Tom Keene, Jonathan Ferro, and Lisa Abramowicz. See omnystudio.com/listener for privacy information.

Moderna CEO Stephane Bancel talks about the Moderna vaccine, drug prices, and future of the company with Bloomberg's Paul Sweeny and Matt Miller. See omnystudio.com/listener for privacy information.

2018 letter shows Michael Cohen lying to feds about Stormy Daniels payment 13:08- Chicago Mayoral Election: Vallas, Johnson spar over Kim Foxx's performance and policing in schools 34:34- Scott Shellady is the Markets Specialist for Market Day Report! – 10:30am CST to 1pm CST- and The Cow Guy Close – 1pm CST to 1:30pm CST – both at RFD-TV. He joined Dan and Amy with reaction to the Federal Reserve decision to raise interest rates. 57:09- Sen. Rand Paul questioned Moderna CEO Stephane Bancel about alleged safety risks for young men after multiple doses of the Covid vaccine 1:12:30- Ed Morrissey is the Senior Editor for HotAir.com. He joined Dan and Amy to talk about the latest developments in the Trump indictment saga. 1:32:42- Karol Markowicz is a columnist for the New York Post and co-author of Stolen Youth: How Radicals Are Erasing Innocence and Indoctrinating a Generation. She joined Dan and Amy to talk about her new column: Your children belong to you, not a school. If you don't fight, you'll lose them. 1:46:52- Dan attempts to help with school board choices.See omnystudio.com/listener for privacy information.

The HighWire's newest addition, News & Editorial contributor, Tracy Beanz has already garnered media attention, breaking open the story of Moderna CEO Stephane Bancel's plan for mRNA technology.#TracyBeanz #mRNA #Moderna #DARPA

In a special episode of Squawk Pod, Joe Kernen, Becky Quick, and Andrew Ross Sorkin are at the World Economic Forum in Davos, Switzerland, where they're speaking with Moderna CEO Stephane Bancel. Three years after the first case of Covid-19 was detected in the United States, Bancel recalls the journey to vaccinating the global public, and Moderna's newest vaccine trials for RSV.In this episode:Stephane Bancel, @moderna_txBecky Quick @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY

Stocks closing well off session highs after Atlanta Fed President Raphael Bostic said the Fed is willing to overshoot. Citi Private Bank Global Head Ida Liu says investors need to buckle up for more volatility, but reveals where she does see buying opportunities right now. Shares of Lululemon plunging after issuing a gross margins warning & Macy's selling off on a sales warning. Former Macy's CEO Terry Lundgren discusses whether retailers are starting to see cracks in consumer spending. Moderna CEO Stephane Bancel discusses his new Covid vaccine pricing strategy for when its government contract ends. And Tilray CEO Irwin Simon discusses the cannabis company's big revenue miss and whether there is any hope for a marijuana legalization bill in Congress now that the House is controlled by the GOP.

FTX Testimony and Moderna's New Drug (Podcast)Mike McGlone, Senior Commodity Strategist with Bloomberg Intelligence, and Nathan Dean, Senior Policy Analyst, US and Latin America with Bloomberg Intelligence, and Katie Greifeld, cross asset reporter with Bloomberg News, join the show to discuss outlook for crypto coins and crypto policy in DC ahead of the testimony of FTX's new CEO. Moderna CEO Stephane Bancel discusses the company's skin cancer drug breakthrough. Annie Massa, cross asset reporter with Bloomberg News, and Barry Ritholtz, host of Bloomberg's "Masters in Business," join to discuss the FTX testimony on Capitol Hill. Hosted by Paul Sweeney and Matt Miller.See omnystudio.com/listener for privacy information.

The Rich Zeoli Show- Full Show (10/19/2022) 3:05pm- At a White House press conference on Wednesday, President Joe Biden announced the release of an additional 15 million barrels of oil from the nation's Strategic Petroleum Reserve (SPR). Biden denied that the new SPR release is politically motivated as we approach November 8th midterms. During the nearly 15-minute address, the President continually abdicated responsibility for increased gas prices.   3:20pm- The Wall Street Journal's Editorial Board documented how “the price of heating fuel will soar this winter, thanks to climate policies.”    3:30pm- In March of 2020, former President Donald Trump advocated on behalf of filling America's Strategic Petroleum Reserves (SPR) while oil prices were low. However, Democrats opposed the measure—calling it a bailout for big oil. On Wednesday, when asked about Democrats' 2020 opposition, as the Biden administration relies upon reserves accumulated under Trump to temporarily lower gas prices, White House Press Secretary Karine Jean Pierre dismissed criticisms by arguing, “it was a different time then.”    3:40pm- Dr. EJ Antoni—Research Fellow for Regional Economics in the Center for Data Analysis at The Heritage Foundation—joins the show to talk about his recent New York Post editorial, “Average American is Losing $34k and Everything Else on Biden's Watch.”   4:05pm- According to reports from Fox News, the Centers for Disease Control and Prevention (CDC) may issue guidance to add the COVID-19 vaccines to the childhood immunization schedule, which could potentially result in vaccination being required in order to attend school. Johns Hopkins Professor Dr. Marty Makary said, if the guidance is ultimately issued by the CDC, it would be despite no clinical data supporting vaccination against COVID-19 for young children being made available to the public.    4:15pm- According to the Daily Mail, when asked about COVID-19 boosters, Moderna CEO Stephane Bancel stated: “If you're a 25-year-old, do you need an annual booster every year if you're healthy? You might want to… but I think it's going to be similar to flu, where it's going to be people at high-risk, people above 50 years of age, people with comorbidities, people with cancer and other conditions, people with transplants.”   4:30pm- Rich somehow manages to break his studio microphone mid-segment…   4:50pm- While appearing on MCNBC's Morning Joe, Democrat candidate for Georgia Governor Stacey Abrams claimed that expanding abortion access is a way to potentially fix inflationary worries, stating: “having children is why you're worried” about a rise in prices.    5:05pm- Fox News reporter Peter Doocy asked White House Press Secretary Karine Jean Pierre if the Biden Administration's attempt to put the oil industry out of business has had an impact on energy availability.   5:10pm- Chess Grandmaster Hans Niemann has been accused of cheating—with some suspecting he has been using a “wireless device” that he “inserted into his rectum.” At the US Chess Championships, Niemann underwent a metal detector sweep. Niemann has admitted to cheating in the past.    5:40pm- Daniel Turner—Founder & Executive Director of Power the Future—joins the show to discuss the Biden Administration's decision to release an additional 15 million barrels of oil from the nation's Strategic Petroleum Reserve (SPR). Turner explains, this is a “desperate election-time band-aid.”    6:05pm- Harvard University's endowment has shrunk by $2.3 billion (a 1.8% negative return)—this comes after the school announced it would discontinue investments within the fossil fuel industry. According to reporting from the Daily Wire, in a letter, Harvard Management Company CEO N.P. Narvekar wrote, Harvard's abandonment of new fossil fuel investments “weighed upon performance.” Similarly, BlackRock has seen its stock downgraded over its embrace of “environmental, social, and governance movement” investing strategies.    6:40pm- The Pennsylvania Department of Conservation and Natural Resources is denying they had anything to do with a series of postings warning of potential Bigfoot encounters in state parks. In a statement, the department emphasized, “Bigfoot is not real.”    6:55pm- Who Won Social Media? + Zeoli's Final Thought ReplyForward

The Rich Zeoli Show- Hour 2:  4:05pm- According to reports from Fox News, the Centers for Disease Control and Prevention (CDC) may issue guidance to add the COVID-19 vaccines to the childhood immunization schedule, which could potentially result in vaccination being required in order to attend school. Johns Hopkins Professor Dr. Marty Makary said, if the guidance is ultimately issued by the CDC, it would be despite no clinical data supporting vaccination against COVID-19 for young children being made available to the public.    4:15pm- According to the Daily Mail, when asked about COVID-19 boosters, Moderna CEO Stephane Bancel stated: “If you're a 25-year-old, do you need an annual booster every year if you're healthy? You might want to… but I think it's going to be similar to flu, where it's going to be people at high-risk, people above 50 years of age, people with comorbidities, people with cancer and other conditions, people with transplants.”   4:30pm- Rich somehow manages to break his studio microphone mid-segment…   4:50pm- While appearing on MCNBC's Morning Joe, Democrat candidate for Georgia  Governor Stacey Abrams claimed that expanding abortion access is a way to potentially fix inflationary worries, stating: “having children is why you're worried” about a rise in prices. 

In today's episode:Masks don't work and actually increased covid deathsNaomi Wolf and her team discover the horrific data on vaccine dangers for pregnant and breastfeeding women and their babies in Pfizer's documents - data that the industry and regulators attempted to hide for 75 yearsModerna CEO Stephane Bancel admits to the WEF there's no demand for vaccines because people don't want themWEF panelist from Oxfam discusses 'profiting off pain', calling covid-19 "the most profitable product ever", while excusing big pharmaAnne Applebaum warmongers in the Atlantic, declaring that defeating Putin is the only acceptable goal in UkraineThe fake administration's China policy regarding Taiwan is incoherent.Connect with Be Reasonable: https://linktr.ee/imyourmoderatorTo support directly:imyourmoderator.substack.comko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: https://cancel-couture.myspreadshop.com/Follow the podcast info stream: t.me/imyourmoderatorOther social platforms: Truth Social, Gab, Rumble, Bitchute, Odysee, DLive or Gettr - @imyourmoderatorVisit mypillow.com and use promo code REASONABLE to support me, Mike Lindell, and his great American company!Listen at: https://shows.acast.com/bereasonable/ or on your favorite podcast app (except Spotify, I'm banned)RSS: https://feeds.acast.com/public/shows/623c9d211c3aa5001204d6ed See acast.com/privacy for privacy and opt-out information. Become a member at https://plus.acast.com/s/be-reasonable-with-your-moderator-chris-paul.

In today's episode:Masks don't work and actually increased covid deathsNaomi Wolf and her team discover the horrific data on vaccine dangers for pregnant and breastfeeding women and their babies in Pfizer's documents - data that the industry and regulators attempted to hide for 75 yearsModerna CEO Stephane Bancel admits to the WEF there's no demand for vaccines because people don't want themWEF panelist from Oxfam discusses 'profiting off pain', calling covid-19 "the most profitable product ever", while excusing big pharmaAnne Applebaum warmongers in the Atlantic, declaring that defeating Putin is the only acceptable goal in UkraineThe fake administration's China policy regarding Taiwan is incoherent.Connect with Be Reasonable: https://linktr.ee/imyourmoderatorTo support directly:imyourmoderator.substack.comko-fi.com/imyourmoderatorbtc via coinbase: 3MEh9J5sRvMfkWd4EWczrFr1iP3DBMcKk5Merch site: https://cancel-couture.myspreadshop.com/Follow the podcast info stream: t.me/imyourmoderatorOther social platforms: Truth Social, Gab, Rumble, Bitchute, Odysee, DLive or Gettr - @imyourmoderatorVisit mypillow.com and use promo code REASONABLE to support me, Mike Lindell, and his great American company!Listen at: https://shows.acast.com/bereasonable/ or on your favorite podcast app (except Spotify, I'm banned)RSS: https://feeds.acast.com/public/shows/623c9d211c3aa5001204d6ed See acast.com/privacy for privacy and opt-out information. Become a member at https://plus.acast.com/s/be-reasonable-with-your-moderator-chris-paul.

Hosts Guy Johnson and Alix Steel talk about the UK windfall tax, the cost of living crisis and PM Boris Johnson's future following Partygate with Bloomberg's Joe Mayes. They also talk earnings with Bloomberg's Katie Greifeld, and about Russia's economy with Bloomberg's Tasos Vossos. Plus, more from Davos, including hearing from Moderna CEO Stephane Bancel, and Rio Tinto CEO Jakob Stausholm.

Hosts Guy Johnson and Eddie van der Walt talk Airbus results with Bloomberg's Charlotte Ryan, hear from Moderna CEO Stephane Bancel about their numbers, discuss the Fed with Bloomberg's Cameron Crise and do a BoE lookahead with Bloomberg's Philip Aldrick.

Larry Fink, CEO and chairman of the world's biggest asset manager BlackRock, wrote in his annual letter that Russia's invasion of Ukraine is reversing the long-running trend of globalization. Blackrock, which oversees more than $10 trillion, has suspended the purchase of any Russian securities in its active or index portfolios. CNBC's Kayla Tausche reports from Brussels, Belgium, where President Biden's and other NATO leaders are meeting to discuss the Russia-Ukraine war. As Covid cases tick upward abroad and begin to tick upward here at home, Moderna CEO Stephane Bancel says the drugmaker wants to provide U.S. regulators “flexibility” in determining eligibility for a fourth Covid vaccine dose. CNBC's Meg Tirrell sits down with Bancel ahead of the company's vaccine day and discusses the company's latest data surrounding its Covid-19 vaccine in young kids. Plus, Google has agreed to test letting app developers offer users their own payment systems, starting with Spotify. In this episode:Stephane Bancel, @moderna_txKayla Tausche, @kaylatauscheMeg Tirrell, @megtirrellAndrew Ross Sorkin, @andrewrsorkinBecky Quick, @BeckyQuickJoe Kernen, @JoeSquawkKatie Kramer, @Kramer_Katie

Moderna CEO Stephane Bancel finds it “reasonable” to think the pandemic might be over, but economies and politics around the world must recover in its wake. Cameron Mitchell, CEO of Cameron Mitchell Restaurants, discusses the increased labor and product costs hitting all restaurateurs, whether Covid ends or not. Arthur Brooks, Harvard professor and The Atlantic contributor, discusses Canada's Prime Minister Justin Trudeau and his approach to truckers protesting vaccine mandates. Brooks considers leadership before and beyond the pandemic: “If you don't love everybody, if you don't believe in the equal dignity of all people, you can't be an effective leader.” The ‘Art of Happiness' podcast host also discusses his new book, ‘From Strength to Strength.' Plus, big media is making big moves, like ViacomCBS's rebrand to Paramount Global, and the Squawk anchors are sharing their game show favorites. In this episode:Arthur Brooks, @arthurbrooksCameron Mitchell, @CMRColumbusJoe Kernen, @JoeSquawkBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_Katie

Let's get into the real reason why Stephane Bancel really sold 400,000,000 dollars worth of Moderna stock and ran off of Twitter. We're gonna unpack it all! --- Support this podcast: https://anchor.fm/rondail-lomax/support

Moderna says giving a full dose of Moderna's Covid-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections. Moderna says preliminary data show antibody response to Omicron at the 50 microgram dose increased 37-fold but when the dose was doubled, antibody levels increased 83-fold. Moderna CEO Stephane Bancel called the results reassuring adding that the company is continuing to develop an Omicron-specific jab. The statement says clinical trials for a targeted vaccine are likely to begin in early 2022.

Moderna says giving a full dose of Moderna's Covid-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections. Moderna says preliminary data show antibody response to Omicron at the 50 microgram dose increased 37-fold but when the dose was doubled, antibody levels increased 83-fold. Moderna CEO Stephane Bancel called the results reassuring adding that the company is continuing to develop an Omicron-specific jab. The statement says clinical trials for a targeted vaccine are likely to begin in early 2022.

Moderna says giving a full dose of Moderna's Covid-19 vaccine as a booster shot provides more antibody protection against the Omicron variant than currently authorised half-strength injections. Moderna says preliminary data show antibody response to Omicron at the 50 microgram dose increased 37-fold but when the dose was doubled, antibody levels increased 83-fold. Moderna CEO Stephane Bancel called the results reassuring adding that the company is continuing to develop an Omicron-specific jab. The statement says clinical trials for a targeted vaccine are likely to begin in early 2022.

The last week brought new evidence regarding the transmissibility, immune evasion and disease severity of Omicron, and with it, more clarity on the coming weeks and months.----- Transcript -----Welcome to Thoughts on the Market. I'm Matthew Harrison, Biotechnology Analyst. Along with my colleagues, bringing you a variety of perspectives, today I'll be discussing our updated thoughts on the COVID 19 pandemic and the impact of Omicron. It's Thursday, December 16th at 10:00 a.m. in New York. Since Omicron was first discovered, we've been using the framework of transmissibility, immune evasion and disease severity to think about its impact. Over the last week, the level of evidence on all three topics has increased significantly. So first, on transmissibility. The ability of Omicron to outcompete the prior dominant variant, Delta, now appears clear. We have evidence in South Africa, the UK and Denmark, with Omicron now dominant in central London and set to be the dominant variant in the UK over the next few days. The US is a few weeks behind Europe in terms of spread, but we would expect a similar pattern. Cases are now rising globally, driven by Omicron's transmissibility. This is a combination of factors driven by one, its innate transmissibility, and second, its immune evasion properties, which have dramatically increased the percentage of the population susceptible to infection. We now have multiple studies, which generally come to a similar conclusion. Two doses of vaccination or a single prior infection provide little to no barrier against infection. Two doses of vaccination do, however, provide protection against severe outcomes like hospitalization or death. This is around a 70% relative reduction versus those who are not vaccinated based on preliminary data. Three doses of vaccination or two doses of vaccination and a prior infection provide a greater barrier against infection. Preliminary data here suggests a 75% relative reduction to those without three doses or two doses and a prior infection. Importantly, since a limited proportion of the population has been boosted - we estimate at about mid-teens percentage of the total US population - the vast majority of the population is again susceptible to an infection with Omicron. And finally, on disease severity. The data out of South Africa continue to suggest the percentage of patients with severe outcomes is lower relative to the prior Delta wave. This means that there are less people in the ICU and less people on a ventilator as a proportion of the total people infected compared with Delta. That said, it's important to remember that even with a lower proportion of people having severe disease, if Omicron drives a wave of infections that is much higher than Delta, the overall disease burden could still be very high. So this leads us to what is our outlook on infections and the ultimate impact of Omicron. The variant is likely to be dominant quickly, and we would expect to be in the steeper part of the exponential rise in cases here in the US in the next two to three weeks. We believe it is possible that the Omicron wave could have a peak in terms of total number of infections that is somewhere between 2 and 3 times higher than the prior Delta wave. However importantly, vaccination should help protect against severe outcomes. For more on Omicron, we also recently sat down for an interview with the Moderna CEO Stephane Bancel to discuss his views on that topic and more. You can see the full interview on MorganStanley.com. Thanks for listening! We hope you have a safe and enjoyable holiday season. If you enjoy Thoughts on the Market, please be sure to rate and review us on the Apple Podcast app. It helps more people find the show.

Bridgewater Associates' Ray Dalio holds firm in his belief that cash is not king, despite the market volatility triggered by the Covid omicron variant. Dalio discusses competing with China, the global economy, and his new book, “The Changing World Order.” Comments about omicron from Moderna CEO Stephane Bancel have spooked investors, and Jack Dorsey's decision to step down from his role as Twitter CEO took the markets by surprise. Plus, for Giving Tuesday: a conversation about the potential for NFTs to innnovate philanthropy with venture capitalist, crypto optimist, blockchain backer and kite surfer Bill Tai. Founder of Metagood and one of the first to make an NFT for charity, Tai discusses paths forward for the metaverse and tech's opportunity to impact positive change. In this episode:Ray Dalio, @RayDalioBill Tai, @KiteVCJoe Kernen, @JoeSquawkBecky Quick, @BeckyQuickAndrew Ross Sorkin, @andrewrsorkinCameron Costa, @CameronCostaNY

Top headlines • Benchmark indices change course to end in red; Sensex drops 196 points • Go Fashion makes stellar stock market debut, lists at 91% premium • Star Health IPO receives lukewarm response; subscribed around 11% on Day 1 • RBI likely to raise rates and tighten monetary policy, says Goldman Sachs • Crypto Bill to be introduced in Parliament after Cabinet's approval Market bulls failed to keep the indices afloat on the bourses on Tuesday after a statement by Moderna chief on vaccines' likely ineffectiveness jolted investor confidence. Although health authorities have said it will take several weeks to fully gauge how Omicron's more than 30 mutations will affect its response to existing vaccines, Moderna CEO Stephane Bancel told the Financial Times that he expected vaccines to be less effective against the new coronavirus strain. Reacting to the development, shares in Asia-Pacific fell during Tuesday's trade. South Korea's Kospi fell 2.4 per cent, while Hong Kong's Hang Seng and Japan's Nikkei slipped 1.9 per cent and 1.6 per cent, respectively. In Europe, the pan-European Stoxx 600 index was down 1.6 per cent by mid-morning. Dow Jones futures were also down by over 500 points, indicating a weak start for Wall Street. Against this backdrop, the Sensex gyrated 1,683 points intra-day and ended 196 points down at 57,065. The NSE Nifty50 also slipped below the 17,000 mark to end at 16,983, down 71 points. Earlier in the day, the 50-pack index hit a low of 16,931. With today's decline, the benchmark indices took their total decline in November to 4 per cent, their biggest monthly loss since March 2020. This correction was triggered by a cocktail of FII selling, high crude oil prices, fears of a possible change in the interest-rate scenario, and the new heavily mutated Covid-19 variant Omicron. Among individual stocks, 17 of the 30 Sensex constituents and 28 of the 50 Nifty constituents ended the day in the red. Tata Steel, Kotak Bank, Bajaj Auto, M&M, Bharti Airtel, and RIL were the biggest losers. The biggest gainers were PowerGrid, Shree Cement, Bajaj Finserv, Titan, and Tata Consumer Products, all of which rose by up to 3 per cent. The broader markets, however, witnessed decent buying, tilting the overall market breadth in the favour of buyers. The BSE MidCap index added 0.3 per cent and the BSE SmallCap index gained 1.45 per cent. A look at some of the other important developments of the day: • Shares of Go Fashion (India) made a stellar market debut today, with the stock getting listed at Rs 1,316 on the BSE. This was a 91-per-cent premium to its issue price of Rs 690. The shares, however, witnessed mild profit booking and ended at Rs 1,253 apiece. • The initial public offering of Ace investor Rakesh Jhunjhunwala-backed Star Health and Allied Insurance has been subscribed 11 per cent so far on Day 1. The retail portion has been subscribed 63 per cent. • Indian online retailer Snapdeal, which is backed by SoftBank Group and Alibaba Group Holding, is planning to file preliminary documents for a $250-million IPO in the next few weeks. According to a Bloomberg report, the e-commerce company aims to go public in early 2022, and plans to raise at least $200 million at a valuation of $1.5 billion. • The Reserve Bank of India could start tightening its monetary policy from the next financial year as consumer prices are rising, according to Goldman Sachs Group. The Group expects the central bank to hike rates by 75 basis points in 2022. • Finance Minister Nirmala Sitharaman has clarified in the Rajya Sabha that the government is not considering a ban on cryptocurrency advertisements and that the crypto Bill will be introduced in Parliament after it receives the Union Cabinet's approval.

Starting Greatness with Mike Maples Podcast Notes Key Takeaways Moderna prioritizes platform over product. For so long, big pharma has created products with analog solutions. Moderna's mRNA technology platform is designed to fork and compound on its base knowledgeto create unique and effective therapeutics quickly.“Golden eggs (drugs) are coming out of the goose (mRNA platform)”– Stephane BancelModerna is not a one drug company – If you can make one drug work safely, you can make many. There is an object-oriented style to this innovation, comparing it to the software world (re-use the knowledge base to other therapeutics).New protein functions are discovered every day. Moderna can not comprehend what kind or how many drug solutions they will have next because the biology of those drugs are not known yetThere are true exponential possibilities for therapeutics through the mRNA platform“Once you understand molecular biology, you start to understand the human body like never before in history”– Stephane BancelStephane Bancel joined Moderna because he saw a 5% chance that their mRNA technology could change the world of medicine forever“We as a species, if we work together, we can do amazing things. I hope this serves as an example of the risks you can take to make the world a better place” – Stephane BancelThe power of entrepreneurship is to invent the future, break the consensus of what can and can not be doneRead the full notes @ podcastnotes.orgWhat's it like to run a startup that has achieved its goal of impacting humanity at a time of desperate need? Moderna CEO Stephane Bancel joins Mike Maples, Jr of FLOODGATE to discuss the power of taking offensive risks to seize unlikely futures with massive upside, sometimes with the result of changing the odds of life itself. For founders seeking greatness, the conversation also teases out many of the enduring lessons of how we can increase the odds of creating massive breakthroughs.

Starting Greatness with Mike Maples Podcast Notes Key Takeaways Moderna prioritizes platform over product. For so long, big pharma has created products with analog solutions. Moderna's mRNA technology platform is designed to fork and compound on its base knowledgeto create unique and effective therapeutics quickly.“Golden eggs (drugs) are coming out of the goose (mRNA platform)”– Stephane BancelModerna is not a one drug company – If you can make one drug work safely, you can make many. There is an object-oriented style to this innovation, comparing it to the software world (re-use the knowledge base to other therapeutics).New protein functions are discovered every day. Moderna can not comprehend what kind or how many drug solutions they will have next because the biology of those drugs are not known yetThere are true exponential possibilities for therapeutics through the mRNA platform“Once you understand molecular biology, you start to understand the human body like never before in history”– Stephane BancelStephane Bancel joined Moderna because he saw a 5% chance that their mRNA technology could change the world of medicine forever“We as a species, if we work together, we can do amazing things. I hope this serves as an example of the risks you can take to make the world a better place” – Stephane BancelThe power of entrepreneurship is to invent the future, break the consensus of what can and can not be doneRead the full notes @ podcastnotes.orgWhat's it like to run a startup that has achieved its goal of impacting humanity at a time of desperate need? Moderna CEO Stephane Bancel joins Mike Maples, Jr of FLOODGATE to discuss the power of taking offensive risks to seize unlikely futures with massive upside, sometimes with the result of changing the odds of life itself. For founders seeking greatness, the conversation also teases out many of the enduring lessons of how we can increase the odds of creating massive breakthroughs.

Moderna CEO Stephane Bancel understands that the task of a revolutionary startup is to manifest a radically different future, and not merely settle for a marginal improvement. But how did he make that future a reality with messenger RNA Therapeutics, and how can you do it with your startup? In this lesson of greatness, Mike Maples, Jr of FLOODGATE goes in-depth on the three strategies to designing a future where your startup achieves greatness: Play offense with risk, use the Backcasting method, and connect the future to the present.

What's it like to run a startup that has achieved its goal of impacting humanity at a time of desperate need? Moderna CEO Stephane Bancel joins Mike Maples, Jr of FLOODGATE to discuss the power of taking offensive risks to seize unlikely futures with massive upside, sometimes with the result of changing the odds of life itself. For founders seeking greatness, the conversation also teases out many of the enduring lessons of how we can increase the odds of creating massive breakthroughs.

mRNA research before COVID and how "mRNA is code" [3:21]The early days of COVID: designing a vaccine in 48 hours [5:44]The software behind the vaccine: getting mRNA researchers out of Excel and into a drug design studio [9:11]The first draft of the vaccine was the final draft [11:10]How the government sped up vaccine development for COVID [12:18]What other new vaccines will come from mRNA?  [15:34]How far are we from these mRNA vaccines? What do we need for them to be widely available? [25:31]Open sourcing Moderna  [27:53]When will COVID vaccines be available for a five year old? [29:47]The three factors that matter when dealing with COVID variants [30:46]How might open source shake up biotech [36:41]The moonshot applications for mRNA therapeutics  [39:43]Advice for building a new category in a regulated environment [46:49]The clinical or regulatory advances needed to speed drug time to market [51:08]Challenge trials for vaccines: good or bad idea? [59:11]It's Time to Heal, Mondays at 5pm PT on Clubhouse. Join the a16z bio team — Jorge Conde, Vineeta Agarwala, Julie Yoo, and Vijay Pande — plus special guests as they explore all the ways that biology is technology.